Introduction of 138199-51-6 :
(RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a highly potent and selective N-methyl-D-aspartate (NMDA) receptor agonist[1]. (RS)-(Tetrazol-5-yl)glycine has EC50s of 99 nM, 1.7 μM for GluN1/GluN2D and GluN1/GluN2A, respectively[2]. (RS)-(Tetrazol-5-yl)glycine induces seizure responses and Fos in mice[3]. IC50 & Target: EC50: 99 nM (GluN1/GluN2D) and 1.7 μM (GluN1/GluN2A)[1] In Vitro: (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine) is a agonist of N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptor. (RS)-(Tetrazol-5-yl)glycine displaces NMDA receptor binding to rat brain membranes as measured using [3H]CGS19755 (IC50=98 nM) and [3H]glutamate (IC50=36 nM) as ligands[1].
(RS)-(Tetrazol-5-yl)glycine does not appreciably inhibit the binding of D,L-alpha-[5-methyl-3H] amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), [3H]kainate, or [3H]glycine (IC50s>30 μM)[1].
In Vivo: (RS)-(Tetrazol-5-yl)glycine (D,L-(tetrazol-5-yl)glycine; 1.25, 1.5 mg/kg; IP) induces seizure responses and Fos in the NR1+/+ and NR1-/- mice[3].
(RS)-(Tetrazol-5-yl)glycine is a highly potent convulsant when given to neonatal rats (ED50=0.071 mg/kg; i.p.) [1].
